ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Cut to $30.00 by Analysts at Royal Bank Of Canada

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective decreased by Royal Bank Of Canada from $31.00 to $30.00 in a research note issued to investors on Thursday morning,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on ACAD. Stifel Nicolaus lowered their price target on shares of ACADIA Pharmaceuticals from $25.00 to $24.00 and set a “hold” rating on the stock in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $34.00 target price on shares of ACADIA Pharmaceuticals in a report on Monday, January 5th. UBS Group increased their price target on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Citigroup lifted their price objective on ACADIA Pharmaceuticals from $33.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Finally, Mizuho upgraded ACADIA Pharmaceuticals from a “neutral” rating to an “outperform” rating and upped their target price for the company from $29.00 to $35.00 in a report on Monday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $30.74.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $24.64 on Thursday. The stock has a 50 day moving average price of $25.58 and a 200 day moving average price of $24.45. ACADIA Pharmaceuticals has a one year low of $13.40 and a one year high of $28.35. The stock has a market capitalization of $4.17 billion, a price-to-earnings ratio of 10.76, a PEG ratio of 8.73 and a beta of 0.66.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, February 25th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $1.48. ACADIA Pharmaceuticals had a net margin of 36.49% and a return on equity of 13.96%. The company had revenue of $298.00 million for the quarter, compared to analysts’ expectations of $292.54 million. During the same quarter in the previous year, the company posted $0.86 EPS. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. On average, analysts predict that ACADIA Pharmaceuticals will post 0.7 earnings per share for the current year.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $23.38, for a total value of $162,491.00. Following the transaction, the executive vice president directly owned 7,609 shares in the company, valued at approximately $177,898.42. This represents a 47.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 26.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Invesco Ltd. boosted its position in shares of ACADIA Pharmaceuticals by 14.5% during the fourth quarter. Invesco Ltd. now owns 847,961 shares of the biopharmaceutical company’s stock worth $22,649,000 after buying an additional 107,386 shares during the period. Mercer Global Advisors Inc. ADV acquired a new position in ACADIA Pharmaceuticals during the 4th quarter worth about $257,000. Mackenzie Financial Corp boosted its holdings in ACADIA Pharmaceuticals by 7.3% during the 4th quarter. Mackenzie Financial Corp now owns 57,274 shares of the biopharmaceutical company’s stock valued at $1,526,000 after acquiring an additional 3,917 shares during the period. Virtus Investment Advisers LLC boosted its holdings in ACADIA Pharmaceuticals by 23.1% during the 4th quarter. Virtus Investment Advisers LLC now owns 25,170 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 4,729 shares during the period. Finally, Sphera Funds Management LTD. grew its position in ACADIA Pharmaceuticals by 42.5% in the 4th quarter. Sphera Funds Management LTD. now owns 212,202 shares of the biopharmaceutical company’s stock valued at $5,668,000 after acquiring an additional 63,302 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors and hedge funds.

ACADIA Pharmaceuticals News Roundup

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat EPS expectations: ACAD reported $1.60 EPS (vs. $0.12 consensus) and $298M revenue, with revenue up ~9% YoY — a clear near-term fundamental positive that supports valuation re-rating. Earnings / Transcript
• Positive Sentiment: Management set 2026 revenue targets of roughly $1.2–$1.28B and highlighted commercial momentum for DAYBUE and NUPLAZID, giving investors a revenue-growth roadmap for next year. Seeking Alpha: 2026 targets
• Positive Sentiment: Multiple analyst actions lifted sentiment — TD Cowen raised its target to $37 (buy), Citizens JMP to $35 (market outperform), and Wolfe Research initiated coverage with an outperform and $33 target — signaling several firms see substantial upside from current levels. Analyst Notes
• Neutral Sentiment: Full earnings materials and call transcript/slide deck are available for detailed review (management commentary covers commercial performance and pipeline updates); useful for investors who want to dig into assumptions behind guidance. Earnings Call Transcript
• Neutral Sentiment: Short-interest reports appearing in data feeds show anomalous zero/NaN values for February; this looks like a reporting glitch and is not a reliable signal of rising short pressure.
• Negative Sentiment: Analysts and headlines flagged an EU setback for trofinetide and a mixed sales read — Zacks notes a sales miss and regulatory/cloud on trofinetide’s EU outlook, which could temper upside for pipeline-derived revenue. Zacks: EU setback
• Negative Sentiment: Some analyst trims introduced headwinds — RBC trimmed its target to $30 and Stifel cut to $24 (hold), creating mixed street sentiment even as other firms raised targets. Analyst Moves
• Negative Sentiment: Broader policy risk for midsize biotechs (debate over MFN / pricing proposals) remains an overhang for the sector and can pressure valuations if regulatory action gains traction. FierceBiotech: Policy risk

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.